Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

By M. Law, N. Wald, Alicja R. Rudnicka. British medical journal, 2003

1,858 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Contradicted and initially stronger effects in highly cited clinical research. (2005, result): “The findings of 20 highly cited articles (44%) were replicated (also with a larger sample size in subsequent research compared with the original highly cited study) and 11 (24%) had remained largely unchallenged.(58-78)”
Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (2005, background): “Thus, atorvastatin, 40–80 mg/day and simvastatin, 40–80 mg/day lower LDL-C levels to a greater extent compared with either fluvastatin, 80 mg/day or pravastatin, 40 mg/day [28].”
Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States (2017, neutral): “7) Diabetes 74 (64, 83) 56 (48, 63) -18 (-21, -15) -24.”
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, result): “Clinical trials of statins generally indicate that each 1% decrease in LDL-C concentration is associated with about a 1% decrease in risk for CHD.(53,107) However, results from epidemiologic and Mendelian randomization studies suggest a larger effect of lower LDL-C levels on CHD in groups with lower”